The In vitro Effect of Nanoliposomal Amphotericin B Against Rhizopus arrhizus Isolated From COVID-19-Associated Mucormycosis Patients.

Q3 Medicine

Iranian Journal of Pathology Pub Date : 2025-01-01 Epub Date: 2025-01-10 DOI:10.30699/ijp.2024.2033626.3320

Ali Ahmadi, Sayed Jamal Hashemi, Seyed Mahdi Rezayat, Roshanak Daie-Ghazvini, Mahmoud Reza Jaafari, Jamileh Esmaeili, Fatemeh Saiedmohammadi, Farzaneh Afshari, Laura Alcazar-Fuoli, Alireza Abdollahi, Sadegh Khodavaisy

{"title":"The In vitro Effect of Nanoliposomal Amphotericin B Against Rhizopus arrhizus Isolated From COVID-19-Associated Mucormycosis Patients.","authors":"Ali Ahmadi, Sayed Jamal Hashemi, Seyed Mahdi Rezayat, Roshanak Daie-Ghazvini, Mahmoud Reza Jaafari, Jamileh Esmaeili, Fatemeh Saiedmohammadi, Farzaneh Afshari, Laura Alcazar-Fuoli, Alireza Abdollahi, Sadegh Khodavaisy","doi":"10.30699/ijp.2024.2033626.3320","DOIUrl":null,"url":null,"abstract":"Background & objective: Rhizopus arrhizus, a major contributor to COVID-19-associated mucormycosis (CAM) globally. Nanoliposomal amphotericin B (NLAmB) presents a promising approach due to its enhanced drug delivery and reduced side effects. This study aimed to assess the in vitro antifungal susceptibility of NLAmB against R. arrhizus isolated from CAM patients.Methods: Thirty-nine R. arrhizus isolated from CAM patients were identified through phenotypic characterization, MALDI-TOF, and the internal transcribed spacer rDNA region (ITS) sequencing approaches. Antifungal susceptibility testing (AFST) for NLAmB, amphotericin B (AmB), posaconazole (PSC), and isavuconazole (ISC) was conducted through broth microdilution methods according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standard E.DEF 9.4. Results were analyzed for MIC ranges, MIC50, MIC90, and distributions.Results: NLAmB demonstrated superior in vitro efficacy against R. arrhizus (MIC50/90, 0.063/0.25 μg/ml) compared to AmB, PSC, and ISC. PSC exhibited notable activity (MIC range: ≤0.031 - ≥16 μg/ml).Conclusion: The study emphasized NLAmB's sustained activity, making it a potential alternative to LAmB. Further exploration and clinical correlation are warranted to validate NLAmB in CAM treatment.","PeriodicalId":38900,"journal":{"name":"Iranian Journal of Pathology","volume":"20 1","pages":"84-89"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887629/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30699/ijp.2024.2033626.3320","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background & objective: Rhizopus arrhizus, a major contributor to COVID-19-associated mucormycosis (CAM) globally. Nanoliposomal amphotericin B (NLAmB) presents a promising approach due to its enhanced drug delivery and reduced side effects. This study aimed to assess the in vitro antifungal susceptibility of NLAmB against R. arrhizus isolated from CAM patients.

Methods: Thirty-nine R. arrhizus isolated from CAM patients were identified through phenotypic characterization, MALDI-TOF, and the internal transcribed spacer rDNA region (ITS) sequencing approaches. Antifungal susceptibility testing (AFST) for NLAmB, amphotericin B (AmB), posaconazole (PSC), and isavuconazole (ISC) was conducted through broth microdilution methods according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standard E.DEF 9.4. Results were analyzed for MIC ranges, MIC50, MIC90, and distributions.

Results: NLAmB demonstrated superior in vitro efficacy against R. arrhizus (MIC50/90, 0.063/0.25 μg/ml) compared to AmB, PSC, and ISC. PSC exhibited notable activity (MIC range: ≤0.031 - ≥16 μg/ml).

Conclusion: The study emphasized NLAmB's sustained activity, making it a potential alternative to LAmB. Further exploration and clinical correlation are warranted to validate NLAmB in CAM treatment.

查看原文本刊更多论文

纳米脂质体两性霉素B对新型冠状病毒相关毛霉病患者分离的阿根霉的体外抑制作用

背景与目的：在全球范围内，新冠肺炎相关毛霉病（CAM）的主要致病源——阿根霉。纳米脂质体两性霉素B （NLAmB）由于其增强药物传递和减少副作用而提出了一种很有前途的方法。本研究旨在评价NLAmB对CAM患者分离的arrhizus的体外抗真菌敏感性。方法：采用表型鉴定、MALDI-TOF和ITS测序等方法对39株CAM患者分离的阿根霉进行鉴定。采用微量肉汤稀释法对NLAmB、两性霉素B （AmB）、泊沙康唑（PSC）和异唑康唑（ISC）进行抗真菌药敏试验（AFST），试验方法参照欧洲抗菌药物敏感性试验委员会（EUCAST）标准E.DEF 9.4。分析结果的MIC范围、MIC50、MIC90和分布。结果：NLAmB对野根霉（MIC50/90, 0.063/0.25 μg/ml）的体外抑菌效果优于AmB、PSC和ISC。PSC具有显著的活性（MIC范围：≤0.031 ~≥16 μg/ml）。结论：该研究强调了NLAmB的持续活性，使其成为LAmB的潜在替代品。需要进一步的探索和临床相关性来验证NLAmB在CAM治疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊